IP Group plc (LSE: IPO), the London-listed investor in breakthrough science and technology companies, has been appointed by Aberdeen Investments to manage a UK venture growth portfolio within the CG Scottish Widows Growth LTAF. The mandate marks one of the first active allocations by a UK defined contribution workplace pension scheme to British venture growth capital, spanning quantum computing, advanced battery technology and AI-enabled healthcare. The arrangement is designed to channel long-term pension savings into high-growth UK innovation companies, with initial investments already identified across four portfolio businesses.

Key Points

  • IP Group plc (LSE: IPO) is the UK's most active early-stage science and technology investor, listed on the London Stock Exchange Main Market
  • Aberdeen Investments has appointed IP Group to manage a UK venture growth portfolio within the CG Scottish Widows Growth LTAF
  • Initial investments are expected to include Oxford Quantum Circuits, Quantum Motion, Nyobolt, and Genomics Limited
  • Investors will be watching whether this mandate expands over time, increasing the flow of long-term pension capital into UK innovation companies

Scottish Widows and Aberdeen Investments Connect Workplace Pension Capital to British Venture Growth

The CG Scottish Widows Growth LTAF is described in the announcement as being amongst the first UK pension schemes to actively allocate members' capital to UK venture growth. Aberdeen Investments manages the growth sub-fund on behalf of Scottish Widows and has now appointed IP Group to oversee the UK venture growth portfolio within it. The structure is intended to bring private markets exposure to workplace pension savers, connecting what the announcement describes as patient institutional capital with high-potential British businesses operating in sectors of strategic importance to the UK economy.

First IP Group Investments Span Quantum Computing, Battery Technology and AI Healthcare

The mandate's initial investments are expected to span four companies from IP Group's existing portfolio of science and technology businesses. Oxford Quantum Circuits is building commercially available quantum computing systems, while Quantum Motion is developing scalable silicon-based quantum computers designed for mass adoption. Nyobolt brings ultra-fast-charging battery technology focused on high-performance energy storage, and Genomics Limited applies artificial intelligence, machine learning and large-scale genetic datasets to preventative healthcare and drug discovery. Together, the announcement states, these investments demonstrate how pension capital can help category-defining UK companies move from scientific leadership to commercial scale.

IP Group's Mandate Targets a Critical Funding Gap in the UK Innovation Economy

The announcement frames the mandate as addressing what it describes as a critical constraint on the UK innovation economy: the availability of meaningful follow-on funding for companies ready to commercialise and expand. IP Group, which also manages Parkwalk — the UK's largest growth EIS fund manager — has previously backed notable companies including Oxford Nanopore Technologies plc, Hinge Health, and Featurespace. The arrangement with Aberdeen Investments and Scottish Widows is described as a model that can be expanded over time, increasing long-term pension capital flows into high-growth UK businesses as part of the Fund's broader global private markets remit.

Scope for Mandate Expansion as UK Pension Reform Drives Private Markets Appetite

The announcement indicates the structure is designed to grow, with the parties stating that the current arrangement represents only the beginning of a larger opportunity. IP Group's chief executive, Aberdeen Investments, and Scottish Widows each issued statements welcoming the partnership, though no specific financial terms, mandate size, or target allocation figures were disclosed in the announcement. Investors may be watching for further details on the scale of capital committed and the timeline for additional portfolio investments as the mandate develops and UK defined contribution pension schemes broaden their exposure to private markets.